3/19
08:08 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
3/18
02:57 pm
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
3/16
04:51 pm
allo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/15
11:05 am
allo
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss [Yahoo! Finance]
Low
Report
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss [Yahoo! Finance]
3/14
06:52 pm
allo
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
3/14
04:21 pm
allo
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update [Yahoo! Finance]
3/14
04:05 pm
allo
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Medium
Report
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
3/13
01:32 pm
allo
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology [Yahoo! Finance]
Low
Report
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology [Yahoo! Finance]
3/12
08:52 am
allo
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease [Yahoo! Finance]
Medium
Report
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease [Yahoo! Finance]
3/12
08:30 am
allo
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Medium
Report
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
3/6
07:00 am
allo
Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements [Yahoo! Finance]
Low
Report
Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements [Yahoo! Finance]
3/5
11:11 am
allo
Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]
Low
Report
Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]
3/5
08:30 am
allo
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Medium
Report
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
2/28
08:30 am
allo
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
Low
Report
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
2/27
02:17 pm
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at JPMorgan Chase & Co. from $9.00 to $8.00. They now have an "overweight" rating on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at JPMorgan Chase & Co. from $9.00 to $8.00. They now have an "overweight" rating on the stock.
2/16
08:36 am
allo
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia [Yahoo! Finance]
Low
Report
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia [Yahoo! Finance]
2/16
08:30 am
allo
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
Low
Report
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
2/12
05:15 am
allo
Solid Tumor Therapeutics Market Size Worth $885.44 Billion by 2033 - Growing Government Initiatives Towards Rising Cancer Cases to Propel Growth [Yahoo! Finance]
High
Report
Solid Tumor Therapeutics Market Size Worth $885.44 Billion by 2033 - Growing Government Initiatives Towards Rising Cancer Cases to Propel Growth [Yahoo! Finance]
2/1
03:28 am
allo
Global DLL3 Targeted Therapy Market Research Report 2024 - Innovations, Opportunities, Market Trends & Clinical Trials Insights [Yahoo! Finance]
Medium
Report
Global DLL3 Targeted Therapy Market Research Report 2024 - Innovations, Opportunities, Market Trends & Clinical Trials Insights [Yahoo! Finance]
1/19
08:04 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $12.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $12.00 to $10.00. They now have a "buy" rating on the stock.
1/16
04:05 pm
allo
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Low
Report
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
1/8
12:32 am
allo
Allogene Therapeutics: A Promising Biotech With A Concerning Lag Time Ahead [Seeking Alpha]
Medium
Report
Allogene Therapeutics: A Promising Biotech With A Concerning Lag Time Ahead [Seeking Alpha]
1/5
02:26 pm
allo
Allogene (ALLO) Down 20% on Strategic Changes in Pipeline [Yahoo! Finance]
Low
Report
Allogene (ALLO) Down 20% on Strategic Changes in Pipeline [Yahoo! Finance]
1/5
08:03 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
1/5
08:02 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "market perform" rating re-affirmed by analysts at JMP Securities.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "market perform" rating re-affirmed by analysts at JMP Securities.